Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

Stopped Impossibility of supplying the medication in research of the study by the pharmaceutical company that gave it to the trial

Conditions

• Liver Transplantation
• Hepatitis C

Interventions

• DRUG: Grazoprevir 100 mg/day
• DRUG: Elbasvir 50 mg/d
• DRUG: Grazoprevir 100 mg/day
• DRUG: Elbasvir 50 mg/day
• DRUG: Ribavirin 1200 mg/day

Sponsor

Fundacion Clinic per a la Recerca Biomédica